US drugmaker Merck & Co announced a deal that could see generic versions of its anti-Covid-19 medication for people infected with the disease widely distributed in poorer countries, AFP reports.

The global Medicines Patent Pool (MPP) said it had signed a voluntary licencing agreement with Merck to facilitate affordable worldwide access for its investigational oral Covid-19 antiviral medicine molnupiravir.

Subject to regulatory approval, the deal will help create broad access for use of molnupiravir in 105 low and middle-income countries.

The US and European Union medicines regulators are already reviewing the drug.

An experimental Covid-19 treatment pill, called molnupiravir, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26. — Reuters
An experimental Covid-19 treatment pill, called molnupiravir, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26. — Reuters

Opinion

Editorial

Budget presser
14 Jun, 2026

Budget presser

OFFICIAL post-budget media briefings in Pakistan are carefully choreographed affairs, full of reassuring phrases ...
Muharram precautions
14 Jun, 2026

Muharram precautions

WITH Muharram due to start next week, the authorities have already begun annual exercises to ensure that the ...
Blood bequests
14 Jun, 2026

Blood bequests

WORLD Blood Donor Day offers a moment of “gratitude, advocacy and renewed commitment” for thalassaemia patients...
Sustainable path?
Updated 13 Jun, 2026

Sustainable path?

The FY27 budget is the first clear signal that the government is ready to transition from stabilisation to growth.
Prioritising education
13 Jun, 2026

Prioritising education

THOUGH the improvement in the country’s literacy rate may be slight, as highlighted by the Economic Survey, it ...
Poverty’s rise
13 Jun, 2026

Poverty’s rise

AS attention turns to the government’s plans for the coming fiscal year, one set of figures deserves particular...